The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesFlow Cyt: Use 0.2µg for 106 cells.
IF: Use at an assay dependent dilution.
Markers for origin of donor and host cells: Use at an assay dependent dilution.
IP: Use at an assay dependent dilution.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
RelevanceCD45 is an essential regulator of leukocyte activation and development, and is now known to be a protein tyrosine phosphatase, e.g. CD45 is able to dephosphorylate the Src family of protein kinases. This activity is now known to be required for signal transduction induced by T and B cell antigen receptor engagement, cytokine signaling and Fc receptor stimulation. The functional state of CD45 also has a pronounced effect on lymphocyte development. CD45 exists in multiple forms, such as the restricted variants and as allelic forms CD45.1/Ly5.1 and CD45.2/Ly5.2. The former arises as a result of alternative splicing of different exons. The specificity of antibodies to CD45.1 and CD45.2 has been exploited in studies in which resolution of donor and recipient cells is essential, such as in gene therapy or bone marrow transplantation.
Protein tyrosine phosphatase receptor type C antibody
Protein tyrosine phosphatase, receptor type, c polypeptide antibody
Receptor type tyrosine protein phosphatase C antibody
T200 glycoprotein antibody
T200 leukocyte common antigen antibody
References for Anti-CD45.1 antibody [A20] (Allophycocyanin) (ab25348)
This product has been referenced in:
Mardiney M & Malech HL Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. Blood87:4049-56 (1996).
Read more (PubMed: 8639760) »
Vallera DA et al. The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation57:249-56 (1994).
Read more (PubMed: 7906058) »